> Chemicals & Drugs > Organic Chemical > PLX 4720

PLX4032 →

PLX 4720

Q: What is PLX 4720?

PLX 4720 is a highly selective BRAF inhibitor that has shown promise in the treatment of various types of cancer, including melanoma and colorectal cancer. It is a key compound used in cancer research and drug development.

Q: How can PubCompare.ai help with PLX 4720 research?

PubCompare.ai is an AI-driven platform that enhances the reproducibility and accuracy of PLX 4720 research. The tool helps users locate the best protocols from literature, pre-prints, and patents by providing AI-driven comparisons to identify the most effective products and procedures. This allows researchers to experience seamless research optimization and choose the best options for their specific goals.

Q: What are some common challenges in using PLX 4720?

One of the main challenges in using PLX 4720 is identifying the most effective protocols and procedures from the vast amount of available information. Researchers may struggle to pinpoint the critical insights needed to ensure reproducibility and accuracy in their experiments. PubCompare.ai can assist by leveraging AI to highlight key differences in protocol effectiveness, making it easier to select the optimal approach.

Q: What are the different variations or types of PLX 4720?

PLX 4720 is primarily available as a pure chemical compound, but there may be slight variations in formulations or delivery methods depending on the specific research application. PubCompare.ai can help researchers compare the performance and characteristics of different PLX 4720 products to determine the most suitable option for their needs.

Q: How can PubCompare.ai help screen PLX 4720 protocol literature more efficiently?

PubCompare.ai's AI-driven platform allows users to quickly and easily screen a large volume of literature related to PLX 4720 protocols. The tool can identify key differences in protocol effectiveness, saving researchers time and effort in finding the most appropriate methods for their specific research goals. This helps optimize the research process and enhances the reproducibility and accuracy of PLX 4720 studies.

Most cited protocols related to «PLX 4720»

Lentiviral ORF Screen for Drug Resistance

Cited 90 times

The arrayed, lentiviral ORF screen was performed as previously described26 (link). Effects of individual ORFs on drug resistance were determined by measuring differential viability (ratio of raw viability in 1 µM PLX4720: control) and subsequent normalization to an assay-specific positive control, MEK1^DD. Secondary screens were performed with the top nine candidate ORFs in 96-well format in A375 and SKMEL28 cells. Prioritization was accomplished via generation of a GI₅₀ for each ORF across a multi-point PLX4720 concentration range in both cell lines. The effects of identified resistance ORFs on MAPK pathway activation were demonstrated using both biochemical and cell biological approaches. Cell line copy number data was obtained as previously described27 (link). Detailed descriptions of all procedures are included in Materials and Methods.

Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., Caponigro G., Hieronymus H., Murray R.R., Salehi-Ashtiani K., Hill D.E., Vidal M., Zhao J.J., Yang X., Alkan O., Kim S., Harris J.L., Wilson C.J., Myer V.E., Finan P.M., Root D.E., Roberts T.M., Golub T., Flaherty K.T., Dummer R., Weber B., Sellers W.R., Schlegel R., Wargo J.A., Hahn W.C, & Garraway L.A. (2010). COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968-972.

Publication 2010

Biological Assay Biopharmaceuticals Cell Lines Cells Open Reading Frames PLX 4720 Resistance, Drug

Genome-wide CRISPR Screening in A375 Cells

Cited 57 times

A375 cells stably integrated with SAM Cas9 and effector components were transduced with SAM sgRNA libraries as described above at an MOI of 0.2, with a minimal representation of 500 transduced cells/guide. Cells were maintained at >500 cells/guide during subsequent passaging. At 7 DPI (complete selection, see above), cells were split into vehicle (DMSO) and PLX-4720 conditions (2 µM PLX-4720 dissolved in DMSO, Selleckchem). Cells were passaged every 2 days for a total of 14 days of drug treatment. >500 cells/guide were harvested as a baseline at 3 DPI (4 days before treatment) and at 21 DPI (after 14 days of treatment) for gDNA extraction. Genomic DNA was extracted using the Zymo Quick-gDNA midi kit (Zymo Research). PCR of the virally integrated guides was performed on gDNA at the equivalent of >500 cells/guide in 96 parallel reactions using NEBnext High Fidelity 2× Master Mix (New England Biolabs) in a single-step reaction of 22 cycles. Primers are listed below:

PCR products from all 96 reactions were pooled, purified using Zymo-Spin™ V with Reservoir (Zymo research) and gel extracted using the Zymoclean™ Gel DNA Recovery Kit (Zymo research). Resulting libraries were deep-sequenced on Illumina MiSeq and HiSeq platforms with a total coverage of >35 million reads passing filter per library.

Konermann S., Brigham M.D., Trevino A.E., Joung J., Abudayyeh O.O., Barcena C., Hsu P.D., Habib N., Gootenberg J.S., Nishimasu H., Nureki O, & Zhang F. (2014). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 517(7536), 583-588.

Publication 2014

Aftercare Cells DNA Library Genome Oligonucleotide Primers Pharmaceutical Preparations PLX 4720 Sulfoxide, Dimethyl

FRET Biosensor Assay in HeLa and Cos7 Cells

Cited 35 times

HeLa cells were purchased from the Human Science Research Resources Bank (Sennanshi, Japan). The Cos7 cells used were Cos7/E3, a subclone of Cos7 cells established by Y. Fukui (National Research Institute of Health, Taiwan, Republic of China). HeLa cells and Cos7 cells were maintained in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS. The cells were plated on 35-mm glass base dishes or 96-well glass base plates (Asahi Techno Glass, Tokyo, Japan), which were coated with collagen type I (Nitta Gelatin, Osaka, Japan). Plasmids encoding FRET biosensors were transfected into HeLa cells and Cos7 cells by 293fectin or Lipofectamine 2000, according to the manufacturer's instructions (Invitrogen, San Diego, CA), respectively. EGF was purchased from Sigma-Aldrich. dbcAMP, TPA, Calyculin A, Anisomycin, PD153035, and JNK inhibitor VIII were purchased from Calbiochem (La Jolla, CA). PD184352 was obtained from Toronto Research Chemicals (Ontario, Canada). BI-D1870 was purchased from Symansis (Shanghai, China). Rapamycin was obtained from LC Laboratories (Woburn, MA). PLX-4720 was purchased from Selleck Chemicals (Houston, TX). The expression vector of piggyBac transposase was provided by A. Bradley (Wellcome Trust Sanger Institute, Cambridge, UK; Yusa et al., 2009 (link)). Phos-tag was obtained from the Phos-tag Consortium (Hiroshima, Japan; www.phos-tag.com). Anti-green fluorescence protein (GFP) sera were prepared in our laboratory. LI-COR (Lincoln, NE) blocking buffer and the IRDye680- and IRDye800-conjugated anti–rabbit and anti–mouse immunoglobulin G secondary antibodies were obtained from LI-COR.

Komatsu N., Aoki K., Yamada M., Yukinaga H., Fujita Y., Kamioka Y, & Matsuda M. (2011). Development of an optimized backbone of FRET biosensors for kinases and GTPases. Molecular Biology of the Cell, 22(23), 4647-4656.

Publication 2011

1,3-bis(bis(pyridin-2-ylmethyl)amino)propan-2-ol Anisomycin Anti-Antibodies BI D1870 Biosensors Bucladesine Buffers calyculin A Cells Cloning Vectors Collagen Type I Fluorescence Resonance Energy Transfer Gelatins Green Fluorescent Proteins HeLa Cells Hyperostosis, Diffuse Idiopathic Skeletal Immunoglobulin G IRDye800 lipofectamine 2000 Manpower Mus PD 153035 PD 184352 Plasmids PLX 4720 Rabbits Serum Sirolimus Transposase

Identifying Synthetic Lethal Interactions in A375 Cells

Cited 30 times

A375 cells stably integrated with dCas9-VP64 and MS2-p65-HSF1 were transduced with individual guides from the top screening hits of the Zeocin and Puromycin screens (13 genes total, 3 sgRNAs per gene) as well as available cDNA at an MOI of <0.2 as described above. Cells were selected for guide expression with Zeocin (Life Technologies) for 5 days and replated at low density (3 × 10³ cells per well in a 96-well plate). A375 cells and A375 cells expressing dCas9-VP64 and MS2-p65-HSF1 were plated as controls. Different concentrations of PLX-4720 (2µM, 0.5µM, 0.15µM) or vehicle (DMSO) were added 3h after plating. Cells were treated with PLX-4720 for 4 days before cell viability was measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega). For qPCR quantification of target gene upregulation, cells were also plated at 5 DPI (3 × 10⁴ cells per well in a 96-well plate) and harvested for mRNA 24h after plating.

Publication 2014

Cells Cell Survival DNA, Complementary Genes Luminescent Measurements PLX 4720 Promega Puromycin RNA, Messenger Sulfoxide, Dimethyl Up-Regulation (Physiology) Zeocin

Microarray Analysis of Neural Crest Development

Cited 10 times

Microarray analysis was performed on 4 groups of 72hpf embryos: 1) WT, 2) mitf-BRAF^V600E, 3) p53^-/- or 4) mitf-BRAF^V600E;p53^-/-. Arrays were similarly performed on adult mitf-BRAF^V600E;p53^-/- melanomas and adjacent skin. The transcriptional signature of the melanomas was used in GSEA to identify genes significantly enriched in the mitf-BRAF^V600E;p53^-/- embryos. This signature (123 genes), enriched for markers of the neural crest, were concordantly up/downregulated in both BRAF^V600E;p53^-/- embryos and tumors. In situ hybridization (ISH) for crestin (a pan NC marker) and other NC genes, was examined in embryos (24-72hpf) and adult tumors. Chemical screening was performed to identify suppressors of the crestin⁺ lineage by treating wild-type embryos from 50% epiboly to 24hpf, followed by robotic ISH. Two inhibitors of DHODH abrogated crestin expression: NSC210627 and leflunomide. The latter was used for further studies due to more widespread availability. The effect of leflunomide on zebrafish embryonic neural crest development was assessed by scoring for embryonic melanocytes, iridophores, and glial cells. Leflunomide was further assessed for its ability to affect multipotent self-renewal of purified p75⁺α₄⁺ rat neural crest stem cells. The effects of leflunomide on transcriptional elongation in the neural crest was tested using the spt5^m806 allele, and measuring pigmentation in response to 3-5uM leflunomide. Elongation in melanoma cells was assayed by ChIP-Seq using an antibody to RNA Polymerase II and measuring the traveling ratio. Leflunomide was tested for anti-melanoma effects in human melanoma cells lines in the presence or absence of the BRAF^V600E inhibitor PLX4720. In vitro proliferation assays were performed using the CellTiterGlo system (Promega). In vivo effects were tested by treatment of established A375 xenografts by daily intraperitoneal dosing of PLX4720 alone, leflunomide alone or the combination, and tumor growth rate measured on day 4, 7 and 12.

White R.M., Cech J., Ratanasirintrawoot S., Lin C.Y., Rahl P.B., Burke C.J., Langdon E., Tomlinson M.L., Mosher J., Kaufman C., Chen F., Long H.K., Kramer M., Datta S., Neuberg D., Granter S., Young R.A., Morrison S., Wheeler G.N, & Zon L.I. (2011). DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature, 471(7339), 518-522.

Publication 2011

Adult Alleles Biological Assay Cell Lines Cells Chromatin Immunoprecipitation Sequencing Dihydroorotate Dehydrogenase Embryo Embryonic Development Genes Heterografts Homo sapiens Immunoglobulins inhibitors In Situ Hybridization Leflunomide Melanocyte Melanoma Microarray Analysis MITF protein, human Neoplasms Neural Crest Neuroglia Pigmentation PLX 4720 Promega RNA Polymerase II Skin Stem Cell Self-Renewal Transcription, Genetic Transcription Elongation, Genetic Zebrafish

Most recents protocols related to «PLX 4720»

Immune Activation Protocol Reagents

The following chemicals and drugs were utilized in this study: Talabostat/VbP (MCE #HY-13233A), Lipofectamine 2000 (Invitrogen #11668019), double-stranded alternating copolymer poly(dA:dT) (pdAdT) (Sigma #P0883), poly(I:C) (pIC) (Invivogen #tlrl-picw), HT-DNA (Sigma #D6898), double-stranded homopolymer poly(dA):poly(dT) (Sigma #P9764), poly(dG:dC) (Invivogen #tlrl-pgcn), PAM3CSK4 (Invivogen #tlrl-pms), nigericin (Sigma #N7143), diABZI (MCE #HY-112921B), ANS (MCE #HY-18982), H₂O₂ (Sigma #H1009), MG-132 (MCE #HY-13259), Bortezomib (MCE #HY-10227), MCC950 (Invivogen #inh-mcc), z-VAD-FMK (Santa Cruz #sc-3067), z-DEVD-FMK (Santa Cruz #sc-311558), H-151 (MCE #HY-112693), NAC (Sigma #A9165), KU-44933 (Santa Cruz #sc-202963), NU-7441 (Tocris #3712), Sorafenib (Sigma #SML2633), PLX-4720 (MCE #HY-51424), Doramapimod (MCE #HY-10320), SB-202190 (MCE #HY-10295), and RNA Polymerase III inhibitor (Sigma #557403). gDNA was isolated from the genomic DNA of HEK293T cells. ISD was synthesized from custom oligos as previously described (55 (link)). Recombinant IFNγ was purchased from Peprotech (#300-02). DNase I (Bio-Rad #7326828), S1 Nuclease (Thermofisher #EN0321), and RNase A/T1 Cocktail (Thermofisher #AM2286) were purchased from the indicated vendors. VACV Copenhagen strain WT and ΔF1L were a kind gift of John Bell (56 (link)) and titered by plaque assay.

Zhou J.Y., Sarkar M.K., Okamura K., Harris J.E., Gudjonsson J.E, & Fitzgerald K.A. (2023). Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT). Proceedings of the National Academy of Sciences of the United States of America, 120(5), e2213777120.

Publication 2023

2',5'-oligoadenylate benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone Biological Assay Bortezomib Cells Dental Plaque Deoxyribonuclease I doramapimod Genome Interferon Type II lipofectamine 2000 MCC-950 MG 132 Nigericin NU 7441 Peroxide, Hydrogen Pharmaceutical Preparations PLX 4720 Poly A Poly I-C Poly T Ribonuclease T1 RNA Polymerase III SB 202190 Sorafenib Strains talabostat

Compound Screening for Drug Discovery

Chemicals used in this study were from the following sources: nilotinib (Selleckchem, S1033), imatinib (Selleckchem, S2475), torin1 (Selleckchem, S2827), Gefitinib (MedChemExpress, HY-50895), GSK621 (Sigma, SML2003), EX229 (MedChemExpress, HY-112769), BC1618 (MedChemExpress, HY-134656), bafilomycin A1 (Selleckchem, S1413), MK2206 (Selleckchem, S1078), SRT1720 (Apexbio, A4180–10), FR180204 (Selleckchem, S7524), PLX-4720 (Selleckchem, S1152). PEG300 (Selleckchem, S6704), DMSO (Sigma, D2650).

Zheng W., Chang I.C., Limberis J., Budzik J.M., Zha B.S., Howard Z., Chen L, & Ernst J.D. (2023). Mycobacterium tuberculosis resides in lysosome-poor monocyte-derived lung cells during chronic infection. bioRxiv.

Publication Preprint 2023

bafilomycin A1 FR 180204 Gefitinib GSK621 Imatinib MK 2206 nilotinib PLX 4720 polyethylene glycol 300 SRT1720 Sulfoxide, Dimethyl

BRAF Mutant Melanoma Cell Lines

BRAF mutant D4M (D4M.7A; RRID:CVCL_0P29) mouse melanoma cells were generated from Tyr::CreER;BrafCA;Ptenlox/lox mice [25 (link)] and were purchased by Kerafast (Boston, MA, USA). BRAF mutant 5555 mouse melanoma cells were established from C57BL/6_BRAF+/LSL‐BRAFV600E;Tyr::CreERT2+/o [26 (link)] and were kindly provided by R. Marais (Cancer Research UK Manchester Institute). D4M cells were cultured in DMEM/F‐12 advanced media (Sigma‐Aldrich, St. Louis, MO, USA) and supplemented with 5% FBS, 1% of penicillin/streptomycin (Sigma‐Aldrich), and 2 mm glutamine (Sigma‐Aldrich). 5555 cells were cultured in DMEM (Sigma‐Aldrich) and supplemented with 10% FBS, 1% of penicillin/streptomycin (Sigma‐Aldrich), and 2 mm glutamine (Sigma‐Aldrich). The cells were grown according to standard protocols in a 37 °C humidified, 5% CO₂ incubator, and were tested regularly for mycoplasma contamination. To authenticate cell lines, cells were confirmed for BRAFV600E mutation by PCR analyses and in vitro sensitivity to PLX4720.

Comunanza V., Gigliotti C., Lamba S., Doronzo G., Vallariello E., Martin V., Isella C., Medico E., Bardelli A., Sangiolo D., Di Nicolantonio F, & Bussolino F. (2023). Dual VEGFA/BRAF targeting boosts PD‐1 blockade in melanoma through GM‐CSF‐mediated infiltration of M1 macrophages. Molecular Oncology, 17(8), 1474-1491.

Full text: Click here

Publication 2023

BRAF protein, human Cell Lines Cells Culture Media Glutamine Hypersensitivity Malignant Neoplasms Melanoma Mus Mutation Mycoplasma Penicillins PLX 4720 Streptomycin

Combinatorial Immunotherapy Protocol

BRAFi (PLX4720) was purchased from Selleck Chemicals (Houston, TX, USA), dissolved in DMSO at a final concentration of 500 mm and stored in aliquots at 80 °C. PLX4720 was administered by daily oral gavage at the dosage of 60 mg·kg⁻¹ (dissolved in a vehicle of 1% w/v methylcellulose in sterile water). The anti‐murine VEGFA (anti‐mVEGFA; B20) was provided by Genentech Inc. (San Francisco, CA, USA) and administered intraperitoneally three times a week (10 mg·kg⁻¹, diluted with sterile 0.9% saline). The anti‐mouse PD‐1 (clone RMP1‐14), anti‐mouse CD8a (clone YTS169.4), anti‐GMCSF (clone MP1‐22E), anti‐CSFR1 (clone AFS98), rat IgG2a (clone 2A3), and rat IgG2b (clone LTF‐2) were purchased from BioXcell (Lebanon, NH, USA). Antibodies were diluted with sterile 0.9% saline Anti‐PD‐1 was administered intraperitoneally three times a week (250 μg per mouse). Anti‐mouse CD8a was used for depletion of CD8⁺ T cells in immunocompetent mice and was injected intraperitoneally on the day of tumor inoculation (400 μg per mouse) and every 3 days throughout the course of the experiments (200 μg per mouse). Anti‐mouse, GM‐CSF, was injected intraperitoneally on the day of tumor inoculation and every 3 days throughout the course of the experiments (250 μg per mouse). Anti‐mouse CSFR1 was injected intraperitoneally on the day of tumor inoculation and every 3 days throughout the course of the experiments (500 μg per mouse). Isotype controls were injected according to the same schedule.

Full text: Click here

Publication 2023

Antibodies Cancer Vaccines CD8-Positive T-Lymphocytes Clone Cells IgG2A IgG2B Immunocompetence Immunoglobulin Isotypes Methylcellulose Mus Normal Saline PLX 4720 sargramostim Sterility, Reproductive Sulfoxide, Dimethyl Tube Feeding

Compound Screening for Drug Discovery

Zheng W., Chang I.C., Limberis J., Budzik J., Zha B.S., Howard Z., Chen L, & Ernst J. (2023). Mycobacterium tuberculosis resides in lysosome-poor monocyte-derived lung cells during chronic infection. Research Square.

Full text: Click here

Publication Preprint 2023

bafilomycin A1 FR 180204 Gefitinib GSK621 Imatinib MK 2206 nilotinib PLX 4720 polyethylene glycol 300 SRT1720 Sulfoxide, Dimethyl

Top products related to «PLX 4720»

Plx4720 by Selleck Chemicals

Sourced in United States

PLX4720 is a small molecule inhibitor that selectively targets the BRAF protein. It is a research tool commonly used in studies related to cell signaling pathways and cancer biology.

Plx4720 by Plexxikon

Sourced in United States

PLX4720 is a small molecule inhibitor that selectively targets the BRAF V600E mutation. It is a laboratory tool used for research purposes.

Trametinib by Selleck Chemicals

Sourced in United States, Germany, United Kingdom, France, China, Italy

Trametinib is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) enzymes 1 and 2. It is a white to almost white crystalline powder that is used in various biomedical research applications.

Vemurafenib by Selleck Chemicals

Sourced in United States, Germany, France, China

Vemurafenib is a laboratory reagent used in research applications. It functions as a kinase inhibitor, specifically targeting the BRAF V600E mutation. This product is intended for research use only and its specific applications may vary depending on the research objectives.

Pd0325901 by Selleck Chemicals

Sourced in United States, Germany, China, United Kingdom, Canada

PD0325901 is a cell-permeable small molecule that selectively inhibits the mitogen-activated protein kinase (MAPK) pathway by targeting MEK1/2. It is commonly used in cell culture research applications.

Sch772984 by Selleck Chemicals

Sourced in United States, China, Germany, United Kingdom, Switzerland

SCH772984 is a chemical compound used in laboratory research. It functions as a small molecule inhibitor. The core purpose of this product is for use in scientific experimentation and analysis.

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Dabrafenib by Selleck Chemicals

Sourced in United States, Germany, France, Italy

Dabrafenib is a small molecule inhibitor of mutant BRAF kinases. It is used as a research tool in the study of BRAF-mediated signaling pathways.

Azd6244 by Selleck Chemicals

Sourced in United States, United Kingdom, China, Germany

AZD6244 is a small molecule inhibitor of the mitogen-activated protein kinase (MAPK) signaling pathway. It specifically targets the MEK enzyme, which is a key component of the MAPK cascade. AZD6244 is commonly used in laboratory research settings to study cell signaling and the role of the MAPK pathway in various biological processes.

Matrigel by BD

Sourced in United States, United Kingdom, Germany, China, Canada, Japan, Italy, France, Belgium, Australia, Uruguay, Switzerland, Israel, India, Spain, Denmark, Morocco, Austria, Brazil, Ireland, Netherlands, Montenegro, Poland

Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. It is widely used as a substrate for the in vitro cultivation of cells, particularly those that require a more physiologically relevant microenvironment for growth and differentiation.

What is PLX 4720?

How can PubCompare.ai help with PLX 4720 research?

PubCompare.ai is an AI-driven platform that enhances the reproducibility and accuracy of PLX 4720 research. The tool helps users locate the best protocols from literature, pre-prints, and patents by providing AI-driven comparisons to identify the most effective products and procedures. This allows researchers to experience seamless research optimization and choose the best options for their specific goals.

What are some common challenges in using PLX 4720?

One of the main challenges in using PLX 4720 is identifying the most effective protocols and procedures from the vast amount of available information. Researchers may struggle to pinpoint the critical insights needed to ensure reproducibility and accuracy in their experiments. PubCompare.ai can assist by leveraging AI to highlight key differences in protocol effectiveness, making it easier to select the optimal approach.

What are the different variations or types of PLX 4720?

How can PubCompare.ai help screen PLX 4720 protocol literature more efficiently?

PubCompare.ai's AI-driven platform allows users to quickly and easily screen a large volume of literature related to PLX 4720 protocols. The tool can identify key differences in protocol effectiveness, saving researchers time and effort in finding the most appropriate methods for their specific research goals. This helps optimize the research process and enhances the reproducibility and accuracy of PLX 4720 studies.

More about "PLX 4720"

PLX 4720 is a highly selective BRAF inhibitor that has shown promise in the treatment of various types of cancer, including melanoma and colorectal cancer.
This AI-driven platform, PubCompare.ai, enhances the reproducibility and accuracy of PLX 4720 research by helping users locate the best protocols from literature, pre-prints, and patents.
The tool provides AI-driven comparisons to identify the most effective products and procedures, optimizing the research process.
PLX4720 is a potent and selective BRAF inhibitor that has demonstrated efficacy in preclinical models of BRAF-mutant cancers, such as melanoma and colorectal cancer.
It works by blocking the activity of the BRAF protein, which is commonly mutated in these types of cancer, leading to uncontrolled cell growth and proliferation.
In addition to PLX4720, other BRAF inhibitors like Vemurafenib, Dabrafenib, and Trametinib have also been developed and studied for the treatment of BRAF-mutant cancers.
These agents work by targeting the BRAF protein and disrupting the MAPK signaling pathway, which is crucial for tumor cell survival and proliferation.
Furthermore, the use of MEK inhibitors, such as Trametinib, PD0325901, and AZD6244, in combination with BRAF inhibitors has shown synergistic effects in inhibiting tumor growth and improving clinical outcomes.
These combination therapies take advantage of the complementary mechanisms of action of the two drug classes, targeting both the BRAF and MEK proteins in the MAPK pathway.
Researchers often utilize cell lines, such as those derived from melanoma or colorectal cancer, to study the effects of these BRAF and MEK inhibitors.
Common experimental conditions include the use of fetal bovine serum (FBS) and extracellular matrix proteins, like Matrigel, to provide a suitable microenvironment for cell growth and proliferation.
PubCompare.ai, the AI-driven platform, can help researchers optimize their PLX4720 research by identifying the most effective protocols and procedures from the literature, pre-prints, and patents.
This tool can enhance the reproducibility and accuracy of PLX4720 studies, ultimately accelerating the development of new therapeutic strategies for BRAF-mutant cancers.